This novel chimeric aptamer-DNAzyme conjugate (NCL-APT-Sur_Dz) demonstrates itself as promising and powerful therapeutics for targeted combating cancer cells through the down-regulation of Sur expression and functionality and consequently allowing for the occurrence of apoptosis in the absence of its inhibitor [84]. The gene discussed is ABCC8; the disease is cancer.